CEFTIN
LOE ApproachingNDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 31m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic approved in 1987 for bacterial infections. The drug is a small-molecule beta-lactam antibiotic indicated for various bacterial infections across multiple therapeutic areas. It represents a mature, well-established antibiotic class with broad clinical utility.
LOE Approaching
As LOE approaches, the brand team is likely consolidating to focus on market defense and pricing optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFTIN represents a late-stage product with minimal job openings and declining career momentum. Roles available are primarily focused on defending market share, managing pricing pressure, and facilitating transition to generic/biosimilar competition rather than driving innovation or growth.
Brand ManagerProduct Manager
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.